Segmented Single-Dose Pill for Hypertension and Hyperlipidemia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Olmesartan medoxomil and rosuvastatin exhibit mutual interference or interaction when combined in a single dosage form, and when combined with amlodipine, the dissolution rate of olmesartan medoxomil decreases, posing challenges for bioequivalence and drug efficacy.

Innovation Solution

A pharmaceutical composition of a single dosage form is developed, comprising separate compartments for olmesartan medoxomil and amlodipine, and another compartment for rosuvastatin, using specific disintegrants and excipients to prevent drug interaction and enhance bioequivalence.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If olmesartan medoxomil, amlodipine, and rosuvastatin are combined in a single dosage form, then patient convenience and compliance are improved, but drug interaction occurs leading to decreased dissolution rate and compromised bioequivalence

Engineering Contradiction:

Improvepatient convenienceVSAvoidbioequivalence

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent divides the single dosage form into separate compartments, with one compartment containing olmesartan medoxomil and amlodipine, and another compartment containing rosuvastatin. This segmentation prevents direct drug interaction between the three medications while maintaining them in a single prescribed unit, thereby preserving both patient convenience and drug bioequivalence.

Inventive Principle:

Principle #1Segmentation

2Productivity

If olmesartan medoxomil and rosuvastatin are combined in a single dosage form, then treatment efficiency is improved, but mutual interference occurs affecting drug dissolution and absorption

Engineering Contradiction:

Improvetreatment efficiencyVSAvoiddrug absorption

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent separates olmesartan medoxomil and rosuvastatin into different compartments within the same dosage form. This physical separation eliminates mutual interference between the two drugs during dissolution, ensuring that each drug maintains its intended absorption characteristics while still providing combined therapeutic effects for hypertension and hyperlipidemia management.

Inventive Principle:

Principle #1Segmentation

3Adaptability or versatility

If olmesartan medoxomil, amlodipine, and rosuvastatin are formulated together, then a comprehensive treatment solution is provided, but the dissolution rate of olmesartan medoxomil decreases

Engineering Contradiction:

Improvecomprehensive treatmentVSAvoiddissolution rate

Core Design Contradiction:

Adaptability or versatilityVSSpeed

Solution Approach 1:

The patent creates separate compartments: one containing olmesartan medoxomil and amlodipine together, and another containing rosuvastatin. This segmentation isolates olmesartan medoxomil from rosuvastatin, preventing the dissolution rate decrease that would occur in a fully mixed formulation, while still providing comprehensive treatment for both hypertension and hyperlipidemia through the combination of all three drugs in a single dosage form.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS12303507B2Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia

Publication Date: 2025.05.20 DAEWOONG PHARM CO LTD

AI summary

The present invention provides a pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia. According to the present invention, compartments comprising a drug are formulated in separate forms so as to solve problems related to the dissolution and absorption of the drug due to drug interaction, and a biologically equivalent preparation can be obtained when compared to conventional single preparation.